Two other pharmaceutical companies have their own oral GLP-1 drugs in the works: Orforglipron: Developed by Eli Lilly, its in Phase 3 clinical trials for treating type 2 diabetes and obesity, with an expected September 2025 completion
& Cahill, G
Noom Hers Nurx PlushCare Ro Alloy WeightWatchers Best of StyleCaster Sign up for Stylecaster's Newsletter
If you are considering both oral supplements and prescription semaglutide therapy, spacing them by at least 2-3 hours can further minimize any mild gastrointestinal overlap
Genetic predispositions revealed by the Precision Peptide Genetic Testspecifically variants in GIPR, FTO, and MC4Rmay help provide context about whether you might benefit from a GLP-1-selective agent like semaglutide versus a dual agonist like tirzepatide, or inform clinical expectations around dosing and tolerability
This extended retention time modifies luminal pH gradients and local oxygen availability, shifting the competitive dynamics between saccharolytic and proteolytic fermentation (76, 77)